Waters Corporation
WAT Healthcare Diagnostics & Research
Waters Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 6.99% from fiscal 2024.
- Revenue
- +120.9%
- EPS
- −67.0%
- Free cash flow
- −66.7%
- Total debt
- +308.2%
Quarter to September 2026, against a year earlier
Follow WAT
Alert me
Waters Corporation (WAT) valuation and DCF model
At $460.26 the price implies free cash flow after share-based pay growing 38.3% a year for ten years.
Free cash flow after share-based pay grew 0.8% a year over the last ten years, −0.5% over the last five. The price asks for more than four times its ten-year rate. The industry’s median company is priced for 15.8%.
In December 2017 the price assumed 8.7% a year; Waters Corporation went on to grow free cash flow after share-based pay −2.8% a year to FY2025.
- The price needs
- 38.3% a year for ten years
- $460.26
- today’s price
- Its base case
- 0.8% a year for five years, then 0.5%
- $35.80
- 92.2% below today’s price
Base case on its own ten-year record Waters Corporation’s own growth, carried forward
Its assumptions
Powerpack lets you start from a scenario and type over any of them.
How we got there$1.18b 10 years of cash to equity+$1.26b terminal value+$593.00m net cash=$3.03b equity value÷84.68m shares=$35.80 per share
Valuation against its own history
| Multiple | Current | 5Y avg | 10Y avg | vs 10Y avg | Industry median | vs industry | 10Y range |
|---|---|---|---|---|---|---|---|
| P/E | 193.97× | 64.61× | 125.18× | 55% above | 34.52× | 462% above | |
| P/FCF | 172.93× | 68.20× | 47.83× | 262% above | 33.51× | 416% above | |
| P/B | 2.94× | 16.35× | 23.14× | 87% below | 3.42× | 14% below | |
| EV/EBITDA | 51.94× | 28.19× | 24.27× | 114% above | 23.44× | 122% above | |
| EV/Sales | 8.73× | 7.68× | 7.27× | 20% above | 5.18× | 69% above |
WAT trades at 51.94× EV/EBITDA, against a 10-year average of 24.27× (range 16.43×–51.94×). That is dearer than 100% of the last 9 year-end readings; re-rating to the average implies $218.78 per share.